Usefulness of transcription-reverse transcription concerted reaction method for detecting circulating tumor cells in patients with colorectal cancer

Annals of Surgical Oncology

Volumn 19, Issue 6, 2012, Pages 2060-2065

  Sato, Nobutaka ^a   Hayashi, Naoko ^a   Imamura, Yu ^a   Tanaka, Yohei ^a   Kinoshita, Koichi ^a   Kurashige, Jyunji ^a   Saito, Seiya ^a   Karashima, Ryuichi ^a   Hirashima, Kotaro ^a   Nagai, Yohei ^a   Miyamoto, Yuji ^a   Iwatsuki, Masaaki ^a   Baba, Yoshifumi ^a   Watanabe, Masayuki ^a   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ASSAY; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; HEALTH CARE COST; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; TRANSCRIPTION REVERSE TRANSCRIPTION CONCERTED REACTION METHOD;

CARCINOEMBRYONIC ANTIGEN; CLINICAL LABORATORY TECHNIQUES; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM MICROMETASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84865135059     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1889-7     Document Type: Article

References (40)

1. Ghossein RA, Scher HI, Gerald WL, et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol. 1995;13:1195-200.
2. Racila E, Euhus D, Weiss AJ, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA. 1998;95:4589-94. (Pubitemid 28207957)
3. Gaforio JJ, Serrano MJ, Sanchez-Rovira P, et al. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer. 2003;107:984-90. (Pubitemid 37429841)
4. Jotsuka T, Okumura Y, Nakano S, et al. Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer. Surgery. 2004;135:419-26. (Pubitemid 38453497)
5. Leather AJ, Gallegos NC, Kocjan G, et al. Detection and enumeration of circulating tumour cells in colorectal cancer. Br J Surg. 1993;80:777-80. (Pubitemid 23197741)
6. Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood. 1993;82:2605-10. (Pubitemid 23318065)
7. Gross HJ, Verwer B, Houck D, et al. Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10(-7). Proc Natl Acad Sci USA. 1995;92:537-41.
8. Johnson PW, Burchill SA, Selby PJ. The molecular detection of circulating tumour cells. Br J Cancer. 1995;72:268-76.
9. Ghossein RA, Rosai J. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. Cancer. 1996; 78:10-6. (Pubitemid 26189898)
10. Mori M, Mimori K, Ueo H, et al. Molecular detection of circulating solid carcinoma cells in the peripheral blood: the concept of early systemic disease. Int J Cancer. 1996;68:739-43. (Pubitemid 27062033)
11. Kruger W, Togel F, Rossing S, et al. Improvement of breast cancer cell detection by immunomagnetic enrichment. Cyto-therapy. 1999;1:135-9.
12. Molnar B, Ladanyi A, Tanko L, et al. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res. 2001;7:4080-5. (Pubitemid 34044631)
13. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897-904. (Pubitemid 39383039)
14. Pierga JY, Bidard FC, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 2008;14:7004-10.
15. Dawood S, Broglio K, Valero V, et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer. 2008;113:2422-30.
16. Goodman OB, Jr., Fink LM, Symanowski JT, et al. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol Biomarkers Prev. 2009;18:1904-13.
17. Hou JM, Greystoke A, Lancashire L, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol. 2009;175:808-16.
18. Fan T, Zhao Q, Chen JJ, et al. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol. 2009;112:185-91.
19. Hiraiwa K, Takeuchi H, Hasegawa H, et al. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol. 2008;15:3092-100.
20. Ishii T, Fujiwara Y, Ohnaka S, et al. Rapid genetic diagnosis with the transcription-reverse transcription concerted reaction system for cancer micrometastasis. Ann Surg Oncol. 2004;11:778-85. (Pubitemid 40486693)
21. Ohashi N, Nakanishi H, Kodera Y, et al. Intraoperative quantitative detection of CEA mRNA in the peritoneal lavage of gastric cancer patients with transcription reverse-transcription concerted (TRC) method. A comparative study with real-time quantitative RT-PCR. Anticancer Res. 2007;27:2769-77. (Pubitemid 47227996)
22. Hayama T, Iinuma H, Watanabe T. Rapid genetic diagnosis with transcription-reverse transcription concerted reaction system for peritoneal recurrence and survival in colorectal cancer patients. Oncol Rep. 2007;18:779-84.
23. Ishikawa T, Miyajima E, Sasaki T, et al. Transcription-reverse transcription concerted reaction and minimal residual disease in axillary sentinel nodes of breast cancer. Eur J Surg Oncol. 2007;33:430-4. (Pubitemid 46586091)
24. Imamura Y, Hayashi N, Sato N, et al. Extensive lymphatic spread of cancer cells in patients with thoracic esophageal squamous cell carcinoma: detection of CEA-mRNA in the three-field lymph nodes. J Surg Oncol. 2010;102:509-15.
25. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:3213-21.
26. Cohen SJ, Punt CJ, Iannotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20:1223-9.
27. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30. (Pubitemid 41095110)
28. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-14.
29. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-7. (Pubitemid 30162806)
30. de Gramont A, Figer A, Seymour M, et al. Leucovorin and flu-orouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-47. (Pubitemid 30644117)
31. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, iri-notecan, and oxaliplatin regardless of whether doublet or singleagent therapy is used first line. J Clin Oncol. 2005;23:9441-2.
32. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42. (Pubitemid 38702844)
33. Cunningham D, Humblet Y, Siena S, et al. Cetuximab mono-therapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-45. (Pubitemid 38944402)
34. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313-27. (Pubitemid 46631379)
35. Iwanicki-Caron I, Di Fiore F, Roque I, et al. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol. 2008;26:3681-6.
36. Tan E, Gouvas N, Nicholls RJ, et al. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 2009;18:15-24.
37. Burt RW, Barthel JS, Dunn KB, et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw. 2010;8:8-61.
38. Sastre J, Maestro ML, Puente J, et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol. 2008;19:935-8. (Pubitemid 351627310)
39. Tol J, Koopman M, Miller MC, et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 2010;21:1006-12.
40. Wang JY, Lin SR, Wu DC, et al. Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. Clin Cancer Res. 2007;13:2406-13.